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CONCLUSION: Superior clinical efficacy combined with
substantial cost savings for at least one year of follow up
conferred to enoxaparin a place of choice in acute cardi-
ology therapy.
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OBJECTIVE: To determine the cost-effectiveness of
thrombosis prevention with Clopidogrel versus Ticlopi-
dine in Russia, taking into account side effect such as
agranulocytosis (neutropenia) using a decision analysis.
METHODS: Pharmacoeconomic comparison using a de-
cision-tree model was based on the assumption that
Ticlopidine (250 mg daily) causes short-duration neutro-
penia in 0,8% of patients compared to 0,04% of patients
on Clopidogrel (37,5 mg daily) one month after treat-
ment starts. The probabilities of neutropenia were de-
rived from multi-center clinical trials of antithrombotic
therapy safety. Calculated costs included cost of study
drugs and direct medical costs for neutropenia treatment.
A neutropenia treatment scheme was analyzed by review-
ing medical charts of patients with short-duration neutro-
penia at the Federal Hematological Center. Effectiveness
was measured by percentage reduction in spontaneous
platelet aggregation (SPA) in a comparative clinical study
including 70 patients with thrombophilia. Cost effective-
ness ratio (CER) was defined for both drugs and incre-
mental cost-effectiveness ratio (ICER) was determined.
RESULTS: The mean costs of medication treatment were
1221 rubles (42,1$) for Clopidogrel and 795 rubles
(27,4$) for Ticlopidine. The median direct medical cost
for treatment of neutropenia was 28,126 rubles (969,9$)
per patient. Expected costs for antiplatelet therapy, tak-
ing into account the probability of neutropenia, was
1020 rubles (35,2$) for Ticlopidine and 1232 rubles
(42,5$) for Clopidogrel. The CER for Clopidogrel was
19,4 rubles (0,67$) and 20,6 rub (0,71$) for Ticlopidine
per 1% of SPA reduction. The ICER for Clopidogrel vs.
Ticlopidine was 14,5 rub (0,5$) per 1% SPA reduction.
CONCLUSION: Clopidogrel is more effective and safe
than Ticlopidine. Though costs for Clopidogrel including
treatment of side effects (neutropenia) were higher than
for Ticlopidine, ICER shows that additional effects can
be achieved at a reasonable cost.
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OBJECTIVE: To conduct an economic analysis of the
PURSUIT trial in the UK for patients with unstable an-
gina or non-Q-wave myocardial infarction (MI) admitted
to hospital and randomized to eptifibatide (GPIIb/IIIa) or
placebo in addition to usual therapy.
METHODS: Health-care resource consumption was col-
lected prospectively for all patients in the PURSUIT trial.
Unit costs were developed for the UK and applied to the
resources consumed in the trial to estimate the cost per
patient treated during index hospital stay and at six
months follow-up. Analyses were conducted using resource
consumption from the UK sub population, Western Eu-
ropean (WE) sub population, and the total PURSUIT trial
population. Long term outcome measures were based on
life expectancy estimated from six-month PURSUIT data of
the WE sub-population and the North American (NA) 
WE sub populations.
RESULTS: Initial hospital and six-month costs for eptifi-
batide patients including drug cost were slightly higher
than the placebo group using the WE and overall trial
population resources. UK-specific resource consumption
was lower in the eptifibatide group. The difference in 30-
day rate of death and MI was 1% (NS) for WE and 1.5%
(p  0.04) for the overall trial. At six months, MI rates
were further decreased for eptifibatide but no difference
existed in mortality between the groups. The CE ratios
(discounted at 3%) using WE or overall resources are
£8,436 and £12,591 respectively using WE survival or
£3,418 and £5,036 using WE  NA survival. Using UK
resources, eptifibatide is cost saving in either survival sce-
nario.
CONCLUSION: The cost-effectiveness ratios for eptifi-
batide in the UK all fall within an acceptable range for
adopting new technology. The impact of resource con-
sumption data on the cost-effectiveness ratio underscores
the importance of the source of treatment-pattern data
and the need for prospective or retrospective data collec-
tion to reflect country-management styles.
PCV10
A PHARMACOECONOMIC ANALYSIS OF 
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OBJECTIVE: The objective of this analysis was to evalu-
ate the health-economic benefits of using amlodipine in
patients undergoing angioplasty procedures from the per-
spectives of the Canadian Ontario Ministry of Health
and the Norwegian National Health Service.
